ACTU Valuation
Actuate Therapeutics Inc
$
7.665
- Overview
- Forecast
- Valuation
- Earnings
ACTU Relative Valuation
ACTU's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACTU is overvalued; if below, it's undervalued.
Historical Valuation
Actuate Therapeutics Inc (ACTU) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.06. The fair price of Actuate Therapeutics Inc (ACTU) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：7.50
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Actuate Therapeutics Inc. (ACTU) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-5.63
EV/EBIT
Actuate Therapeutics Inc. (ACTU) has a current EV/EBIT of -5.63. The 5-year average EV/EBIT is -2.85. The thresholds are as follows: Strongly Undervalued below -8.30, Undervalued between -8.30 and -5.57, Fairly Valued between -0.12 and -5.57, Overvalued between -0.12 and 2.61, and Strongly Overvalued above 2.61. The current Forward EV/EBIT of -5.63 falls within the Undervalued range.
0.00
PS
Actuate Therapeutics Inc. (ACTU) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Actuate Therapeutics Inc. (ACTU) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
-6.12
P/FCF
Actuate Therapeutics Inc. (ACTU) has a current P/FCF of -6.12. The 5-year average P/FCF is -2.03. The thresholds are as follows: Strongly Undervalued below -7.95, Undervalued between -7.95 and -4.99, Fairly Valued between 0.93 and -4.99, Overvalued between 0.93 and 3.89, and Strongly Overvalued above 3.89. The current Forward P/FCF of -6.12 falls within the Undervalued range.
Actuate Therapeutics Inc (ACTU) has a current Price-to-Book (P/B) ratio of -61.48. Compared to its 3-year average P/B ratio of 195.01 , the current P/B ratio is approximately -131.53% higher. Relative to its 5-year average P/B ratio of 195.01, the current P/B ratio is about -131.53% higher. Actuate Therapeutics Inc (ACTU) has a Forward Free Cash Flow (FCF) yield of approximately -13.27%. Compared to its 3-year average FCF yield of -13.84%, the current FCF yield is approximately -4.08% lower. Relative to its 5-year average FCF yield of -13.84% , the current FCF yield is about -4.08% lower.
-59.20
P/B
Median3y
195.01
Median5y
195.01
-13.74
FCF Yield
Median3y
-13.84
Median5y
-13.84
Competitors Valuation Multiple
The average P/S ratio for ACTU's competitors is 0.93, providing a benchmark for relative valuation. Actuate Therapeutics Inc Corp (ACTU) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ACTU increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ACTU in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Actuate Therapeutics Inc (ACTU) currently overvalued or undervalued?
Actuate Therapeutics Inc (ACTU) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.06. The fair price of Actuate Therapeutics Inc (ACTU) is between to according to relative valuation methord.
What is Actuate Therapeutics Inc (ACTU) fair value?
How does ACTU's valuation metrics compare to the industry average?
What is the current P/B ratio for Actuate Therapeutics Inc (ACTU) as of Aug 22 2025?
What is the current FCF Yield for Actuate Therapeutics Inc (ACTU) as of Aug 22 2025?
What is the current Forward P/E ratio for Actuate Therapeutics Inc (ACTU) as of Aug 22 2025?